Under the current structure,and the current business plan, fully diluted means 150 million shares, maximum. Current funding is sufficient to take Prurisol to market and complete Kevetrin Phase 1 studies with what I estimate as a $4 million funding reserve. Current business plan is to license or sell after Phase 1 Kevetrin results or Phase 2/3 Prurisol. Either way, the cap remains under valued when compared to dozens of other small biotechs at similar points in development and with no where near the potential of either drug, much less both.
None of the above should change unless there is some negative result from one of the drugs. Pre-clinical data and the presence of Harvard, DF/BI/Pfizer all suggest that is highly unlikely.
News 
Market Data 
Discover 
AI
